IN2014DN10996A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN10996A IN2014DN10996A IN10996DEN2014A IN2014DN10996A IN 2014DN10996 A IN2014DN10996 A IN 2014DN10996A IN 10996DEN2014 A IN10996DEN2014 A IN 10996DEN2014A IN 2014DN10996 A IN2014DN10996 A IN 2014DN10996A
- Authority
- IN
- India
- Prior art keywords
- dna sequence
- composition
- targeted
- alteration
- minivector
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 4
- 230000004075 alteration Effects 0.000 abstract 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653279P | 2012-05-30 | 2012-05-30 | |
PCT/US2013/043433 WO2013181440A1 (en) | 2012-05-30 | 2013-05-30 | Supercoiled minivectors as a tool for dna repair, alteration and replacement |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN10996A true IN2014DN10996A (enrdf_load_stackoverflow) | 2015-09-25 |
Family
ID=49673908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN10996DEN2014 IN2014DN10996A (enrdf_load_stackoverflow) | 2012-05-30 | 2013-05-30 |
Country Status (10)
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
RS57287B1 (sr) | 2012-05-25 | 2018-08-31 | Univ California | Postupci i sastavi za rnk-usmerenu modifikaciju ciljane dnk i za rnk-usmerenu modulaciju transkripcije |
LT3138910T (lt) | 2012-12-06 | 2017-11-10 | Sigma-Aldrich Co. Llc | Crispr pagrįstas genomo modifikavimas ir reguliavimas |
CN111454951A (zh) | 2013-03-14 | 2020-07-28 | 卡里布生物科学公司 | 以核酸为靶的核酸的组合物和方法 |
AU2014262867B2 (en) | 2013-05-10 | 2019-12-05 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US20150079680A1 (en) | 2013-09-18 | 2015-03-19 | Kymab Limited | Methods, cells & organisms |
DK3066201T3 (en) | 2013-11-07 | 2018-06-06 | Editas Medicine Inc | CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
MX2016012716A (es) * | 2014-03-28 | 2017-08-16 | Aposense Ltd | Compuestos y metodos para suministro trans-membrana de moleculas. |
US11318206B2 (en) | 2014-03-28 | 2022-05-03 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
JP6765968B2 (ja) | 2014-04-10 | 2020-10-07 | シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート | 薬物制御による導入遺伝子の発現 |
AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
US11071289B2 (en) | 2014-08-14 | 2021-07-27 | Biocytogen Boston Corp | DNA knock-in system |
WO2016057961A1 (en) | 2014-10-10 | 2016-04-14 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
EP4464338A3 (en) | 2014-11-07 | 2025-02-12 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
CN105821072A (zh) * | 2015-01-23 | 2016-08-03 | 深圳华大基因研究院 | 用于DNA组装的CRISPR-Cas9系统及DNA组装方法 |
JP7162530B2 (ja) | 2015-08-07 | 2022-10-28 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | 固形腫瘍を標的とする二重特異性car t細胞 |
AU2016326711B2 (en) | 2015-09-24 | 2022-11-03 | Editas Medicine, Inc. | Use of exonucleases to improve CRISPR/Cas-mediated genome editing |
IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and uses thereof |
WO2017147278A1 (en) | 2016-02-25 | 2017-08-31 | The Children's Medical Center Corporation | Customized class switch of immunoglobulin genes in lymphoma and hybridoma by crispr/cas9 technology |
EP3219803A1 (en) * | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum für Molekulare Medizin | Enhanced sleeping beauty transposons, kits and methods of transposition |
US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
EP3443086B1 (en) | 2016-04-13 | 2021-11-24 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
EA201892810A1 (ru) | 2016-06-01 | 2019-06-28 | Квс Заат Се | Гибридные последовательности нуклеиновых кислот для геномной инженерии |
ES2817973T3 (es) | 2016-07-01 | 2021-04-08 | Microsoft Technology Licensing Llc | Almacenamiento a través de la edición iterativa del ADN |
US11359234B2 (en) | 2016-07-01 | 2022-06-14 | Microsoft Technology Licensing, Llc | Barcoding sequences for identification of gene expression |
US10892034B2 (en) | 2016-07-01 | 2021-01-12 | Microsoft Technology Licensing, Llc | Use of homology direct repair to record timing of a molecular event |
IL264565B2 (en) | 2016-08-03 | 2024-07-01 | Harvard College | Adenosine nuclear base editors and their uses |
JP7201153B2 (ja) | 2016-08-09 | 2023-01-10 | プレジデント アンド フェローズ オブ ハーバード カレッジ | プログラム可能cas9-リコンビナーゼ融合タンパク質およびその使用 |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN109937209A (zh) | 2016-10-10 | 2019-06-25 | 利马格兰集团 | 编码对橙色小麦花蚊的sm1抗性的核酸及使用方法 |
WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
WO2018144097A1 (en) | 2016-11-04 | 2018-08-09 | Akeagen Llc | Genetically modified non-human animals and methods for producing heavy chain-only antibodies |
AU2017375630B2 (en) | 2016-12-12 | 2023-12-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
JP7348064B2 (ja) | 2017-01-09 | 2023-09-20 | アポセンス リミテッド | 分子を経膜送達するための化合物及び方法 |
KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US20180305701A1 (en) | 2017-03-14 | 2018-10-25 | Baylor College Of Medicine | Targeting minivectors to specific tissue using shape |
KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
WO2019068800A1 (en) | 2017-10-05 | 2019-04-11 | Biogemma | IMPROVED YIELD IN PLANTS BY OVEREXPRESSION OF A TRHEHALOSE-6 PHOSPHATE SYNTHASE |
KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
WO2019086510A1 (en) | 2017-10-31 | 2019-05-09 | Vilmorin & Cie | Wheat comprising male fertility restorer alleles |
US20200048716A1 (en) | 2017-11-03 | 2020-02-13 | Twister Biotech, Inc | Using minivectors to treat ovarian cancer |
BR112020008919A2 (pt) * | 2017-11-21 | 2020-10-20 | Monsanto Technology Llc | plantas modificadas com traços aprimorados |
US12337036B2 (en) | 2018-01-01 | 2025-06-24 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
GB201805865D0 (en) | 2018-04-09 | 2018-05-23 | Innes John Centre | Genes |
US20210346306A1 (en) | 2018-05-23 | 2021-11-11 | Modernatx, Inc. | Delivery of dna |
EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
WO2020161261A1 (en) | 2019-02-06 | 2020-08-13 | Vilmorin & Cie | New gene responsible for cytoplasmic male sterility |
WO2020191248A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Method and compositions for editing nucleotide sequences |
EP3993612A1 (en) | 2019-07-05 | 2022-05-11 | Limagrain Europe | Method for increasing yield in plants |
FR3099178A1 (fr) | 2019-07-24 | 2021-01-29 | Soltis | Tournesol à teneur élevée en acide oléique et procédé d’obtention |
CA3151464A1 (en) | 2019-09-18 | 2021-03-25 | Bruce C. SCHNEPP | Synthetic dna vectors and methods of use |
CN112779266A (zh) | 2019-11-06 | 2021-05-11 | 青岛清原化合物有限公司 | 在生物体内创制新基因的方法及应用 |
US20230123128A1 (en) * | 2020-04-03 | 2023-04-20 | Progenitor Life Sciences | Targeting tapasin and tap complex to improve cellular immune-compatibility |
KR20230019843A (ko) | 2020-05-08 | 2023-02-09 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물 |
WO2021247507A1 (en) | 2020-06-01 | 2021-12-09 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
EP4337177A1 (en) | 2021-05-11 | 2024-03-20 | Modernatx, Inc. | Non-viral delivery of dna for prolonged polypeptide expression in vivo |
US20240093226A1 (en) | 2021-09-10 | 2024-03-21 | Baylor College Of Medicine | Ultrapure minivectors for gene therapy |
US20240100189A1 (en) | 2021-09-10 | 2024-03-28 | Twister Biotech, Inc | Using minivectors to treat idiopathic pulmonary fibrosis |
US20230190955A1 (en) | 2021-10-21 | 2023-06-22 | Baylor College Of Medicine | Treatment of liver cancer or liver fibrosis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1100201A (en) * | 1999-10-28 | 2001-05-08 | Board Of Trustees Of The Leland Stanford Junior University | Methods of in vivo gene transfer using a sleeping beauty transposon system |
US20100076057A1 (en) * | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
CA2777835A1 (en) * | 2009-10-16 | 2011-04-21 | Baylor College Of Medicine | Supercoiled minicircle dna for gene therapy applications |
US9125385B2 (en) * | 2010-11-12 | 2015-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Site-directed integration of transgenes in mammals |
EP3839050A3 (en) * | 2012-04-18 | 2021-09-29 | The Board of Trustees of the Leland Stanford Junior University | Non-disruptive gene targeting |
-
2013
- 2013-05-30 EP EP13798043.9A patent/EP2854866A4/en not_active Withdrawn
- 2013-05-30 BR BR112014030007A patent/BR112014030007A2/pt not_active IP Right Cessation
- 2013-05-30 IN IN10996DEN2014 patent/IN2014DN10996A/en unknown
- 2013-05-30 AU AU2013267350A patent/AU2013267350A1/en not_active Abandoned
- 2013-05-30 KR KR1020147035278A patent/KR20150027756A/ko not_active Withdrawn
- 2013-05-30 JP JP2015515201A patent/JP2015523860A/ja not_active Ceased
- 2013-05-30 WO PCT/US2013/043433 patent/WO2013181440A1/en active Application Filing
- 2013-05-30 US US13/906,130 patent/US20140056868A1/en not_active Abandoned
- 2013-05-30 CA CA2876860A patent/CA2876860A1/en not_active Abandoned
- 2013-05-30 US US14/404,736 patent/US20150376645A1/en not_active Abandoned
- 2013-05-30 MX MX2014014650A patent/MX2014014650A/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014030007A2 (pt) | 2017-06-27 |
JP2015523860A (ja) | 2015-08-20 |
US20150376645A1 (en) | 2015-12-31 |
CA2876860A1 (en) | 2013-12-05 |
AU2013267350A1 (en) | 2015-01-29 |
MX2014014650A (es) | 2015-10-14 |
US20140056868A1 (en) | 2014-02-27 |
EP2854866A1 (en) | 2015-04-08 |
EP2854866A4 (en) | 2015-12-23 |
WO2013181440A1 (en) | 2013-12-05 |
KR20150027756A (ko) | 2015-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN10996A (enrdf_load_stackoverflow) | ||
IL273159A (en) | A culture medium preparation, and a method for culturing cells or tissues by using the preparation | |
MX2012013037A (es) | Composiciones de endorribonucleasa y metodos de uso de las mismas. | |
MX2022003477A (es) | Medio de cultivo celular complementado con taurina y metodos de uso. | |
MX2015004649A (es) | Metodos de modificacion de celulas huesped. | |
MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
WO2012021632A3 (en) | Generation and use of pluripotent stem cells | |
SG10201808863UA (en) | Combined chemical and genetic approaches for generation of induced pluripotent stem cells | |
MX2018010529A (es) | Composiciones y metodos para la produccion y administracion de acido ribonucleico. | |
SG10201809901SA (en) | Generating Pluripotent Cells De Novo | |
MX2017004890A (es) | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. | |
MX344970B (es) | Medio de cultivo celular para la expresion de la proteina adamts. | |
EP4372081A3 (en) | Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect | |
MX2015005797A (es) | Produccion de vacuna recombinante en e.coli mediante conjugacion enzimatica. | |
MX2010000348A (es) | Cultivo de celulas madre pluripotentes individuales. | |
IN2014MN01680A (enrdf_load_stackoverflow) | ||
MY194500A (en) | Methods and Compositions for Producing Fatty Alcohols | |
BR112014031424A2 (pt) | tratamento de células pluripotentes | |
MX2015007361A (es) | Produccion mediada por la proteina portadora de acilo de los derivados de acidos grasos. | |
SG10201809452RA (en) | Cell culture compositions with antioxidants and methods for polypeptide production | |
MY173663A (en) | Compositions and methods for biological production of fatty acid derivatives | |
EP2588594A4 (en) | METHODS FOR CULTURING INDIFFERENCED CELLS USING EXTENDED RELEASE COMPOSITIONS | |
MY197970A (en) | Microorganisms and methods for the production of caprolactone | |
IN2014DN11272A (enrdf_load_stackoverflow) | ||
MY180183A (en) | Methods and compositions for preventing norleucine misincorporation into proteins |